Does tesamorelin reduce visceral fat?
Yes — tesamorelin is FDA-approved for visceral fat reduction in HIV lipodystrophy, with ~15–20% reductions in controlled trials. Off-label interest is growing.
Updated May 9, 2026 · 4 min read
Yes — and tesamorelin is the only GH-related peptide with actual FDA approval for this purpose, backed by Phase 3 clinical trials. It's approved under the brand name Egrifta for the treatment of HIV-associated lipodystrophy, a condition where antiretroviral therapy causes abnormal visceral fat accumulation. The trials are unusually rigorous by peptide standards: randomized, double-blind, placebo-controlled, and measuring hard endpoints (CT-measured visceral adipose tissue, or VAT). Off-label use in healthy adults for body recomposition is growing, partly because it's the one GH secretagogue where you're not just extrapolating from animal data.
What tesamorelin is
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) — the same class as CJC-1295 and Sermorelin, but stabilized with a trans-3-hexenoic acid group that significantly extends its half-life and potency. It works by stimulating the pituitary to release GH, which then drives IGF-1 production, which in turn promotes lipolysis (fat breakdown) with a particular affinity for visceral adipose tissue.
Visceral fat (the fat around the organs, inside the abdominal cavity) is uniquely responsive to GH and IGF-1 signaling. This is why GH deficiency is associated with visceral fat accumulation, and why GH-restoring interventions tend to reduce it preferentially — not just total fat.
What the clinical data shows
The landmark trials (LIPO-010A and LIPO-010B) studied tesamorelin 2 mg/day in HIV-positive patients with lipodystrophy over 26 weeks:
| Endpoint | Tesamorelin | Placebo |
|---|---|---|
| VAT reduction (CT-measured) | ~15–20% | ~3–5% |
| Triglycerides | Significant reduction | Minimal change |
| IGF-1 | Significant increase | No change |
| Lean mass | Slight increase | No change |
| Glucose / HbA1c | Slight worsening | Minimal change |
The glucose effect is the important caveat: tesamorelin increases IGF-1, which can transiently worsen insulin sensitivity — particularly in users who already have impaired glucose regulation. In the trials, this was manageable and didn't lead to significant diabetes risk in this population, but it's a real signal that needs monitoring.
After 26 weeks of treatment, stopping tesamorelin resulted in the visceral fat returning toward baseline within a few months. It suppresses visceral fat rather than permanently resetting it.
How it differs from other GH secretagogues
| Agent | FDA approval | VAT evidence | Half-life | Dosing frequency |
|---|---|---|---|---|
| Tesamorelin | Yes (Egrifta) | Phase 3 RCT | ~30 min (but trans-3-hexenoic stabilization extends activity) | Daily injection |
| CJC-1295 (no-DAC) | No | Animal/N=1 | ~30 min | Daily or BID |
| CJC-1295 (DAC) | No | Animal/N=1 | ~8 days | 1–2× per week |
| Sermorelin | No | Limited human data | ~10–15 min | Daily or BID |
| GHRP-2/6, Ipamorelin | No | Animal/N=1 | Short | Daily |
Tesamorelin's advantage is that you know what it does in humans because someone measured it rigorously. The disadvantage is cost: as a branded pharmaceutical (Egrifta), it's expensive, and compounded versions are available but sit in a regulatory grey zone similar to other compounded peptides.
What off-label users report
The self-experimentation community using tesamorelin for general body recomposition (rather than HIV lipodystrophy) reports:
- Noticeable reduction in abdominal fullness within 4–8 weeks
- CGM users often see glucose variability increase slightly, particularly after carbohydrate meals
- Some report improved body composition metrics even without weight loss
- Effects plateau after 3–4 months if the dose isn't adjusted; many cycle it
Typical off-label protocol
There is no evidence-based off-label protocol. The following is drawn from the clinical trial design and self-experimentation adaptations:
| Parameter | Common approach |
|---|---|
| Dose | 1–2 mg/day |
| Route | Subcutaneous injection |
| Timing | Before bed or in the morning, fasted |
| Cycle length | 3–6 months |
| Monitoring | IGF-1, fasting glucose, HbA1c at baseline and 3 months |
The standard clinical dose is 2 mg/day. Some off-label users start at 1 mg to assess tolerance, particularly around glucose.
Who should be careful
- People with pre-diabetes or diabetes: the glucose impact is real and needs monitoring; discuss with a clinician before using
- Active malignancy: like all GH-axis interventions, tesamorelin carries theoretical concern in an oncological context
- Carpal tunnel or joint pain history: elevated IGF-1 can worsen or trigger CTS and arthralgias
- Hypothyroidism: GH elevation can accelerate thyroid hormone metabolism; thyroid function should be checked if symptoms appear
Is it worth it over other GH secretagogues?
For pure visceral fat reduction, tesamorelin has the best evidence of any peptide in this category. If that's the specific goal, it's a reasonable choice for adults who understand the metabolic trade-offs. For general recovery, sleep quality, or muscle support, ipamorelin/CJC-1295 is cheaper, more accessible, and well-supported enough for most users.